Background In the AVERROES study, apixaban, a novel factor Xa inhibitor, reduced the risk
of stroke or systemic embolism in patients with atrial fibrillation who were at high risk of …

Background Patients with atrial fibrillation (AF) often have multi-morbidity, defined as≥ 3
comorbid conditions. Multi-morbidity is associated with polypharmacy, adverse events, and …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …

Aims We investigated baseline characteristics, antithrombotic use, and clinical outcomes of
patients with atrial fibrillation (AF) and a thrombo-embolic event in the Apixaban for …

Aims The ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events
in Atrial Fibrillation) trial randomised patients with atrial fibrillation at risk of stroke to …

Vitamin K antagonists (eg warfarin) are commonly underutilised, due to limitations such as
the need for monitoring, in high-risk atrial fibrillation (AF) patients. We therefore aimed to …

Abstract Aim In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced the risk of …

Abstract Aims Using Scandinavian population-based registries, we assessed risk of
stroke/systemic embolism (SE) and bleeding with non-vitamin K antagonist oral …

Background: Patients with atrial fibrillation (AF) and coronary artery disease (CAD) are at
high risk for ischemic and bleeding events, and warfarin is known to reduce coronary events …

Background: Patients at low risk of stroke were not included in the trials that lead to the
approval of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in …